FDA 483 - Loop Plaza Pharmacy Company DBA Loop Compounding Pharmacy - September 25, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
On September 19-21 and 24-25, 2018, the FDA inspected Loop Plaza Pharmacy Company DBA Loop Compounding Phar, located at 72 6th Ave, Saint Albans, WV. The firm is a producer of sterile and non-sterile drug products. The inspection revealed four observations.
Observation 1 noted that the ISO 5 classified area is within a non-classified room, lacking assurance of classified conditions for the cleanroom surrounding the ISO 5 laminar air flow hood. The last certification was on February 22, 2018, and was overdue for re-certification, with approximately 200 products produced since September.
Observation 2 identified the use of non-sterilized or non-depyrogenated tools or temporary containers in sterile drug production, specifically for storing bulk solutions. This raises concerns about sterility maintenance for products like Bupivacaine HCl 40mg/ml, Hydromorphone 100mg/ml, Morphine 100mg/ml, and Clonidine HCl 2000 mcg/ml, which are used for patient-specific prescriptions.
Observation 3, a repeat observation from a previous inspection, stated that ISO-5 classified areas were not certified under dynamic conditions. Specifically, no dynamic smoke studies were performed during the February 22, 2018 cleanroom certification to verify unidirectional airflow in the
- Inspection Date
- September 25, 2018
ID · b6e52571-a039-4e36-8f59-7c15eb2ad608